170 related articles for article (PubMed ID: 38553451)
21. Selective targeting p53
Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
[TBL] [Abstract][Full Text] [Related]
22. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma X; Rousseau V; Sun H; Lantuejoul S; Filipits M; Pirker R; Popper H; Mendiboure J; Vataire AL; Le Chevalier T; Soria JC; Brambilla E; Dunant A; Hainaut P;
Mol Oncol; 2014 May; 8(3):555-64. PubMed ID: 24495481
[TBL] [Abstract][Full Text] [Related]
23. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
24. Dexamethasone reduces sensitivity to cisplatin by blunting p53-dependent cellular senescence in non-small cell lung cancer.
Ge H; Ni S; Wang X; Xu N; Liu Y; Wang X; Wang L; Song D; Song Y; Bai C
PLoS One; 2012; 7(12):e51821. PubMed ID: 23272171
[TBL] [Abstract][Full Text] [Related]
25. Loss of EPS8 sensitizes non-small-cell lung carcinoma to chemotherapy-induced DNA damage.
Qiu Y; Xu B; Feng J; Wang C; Chen Y; He Y; Xie X; Li Y
Cancer Gene Ther; 2023 Jul; 30(7):997-1006. PubMed ID: 36932195
[TBL] [Abstract][Full Text] [Related]
26. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer.
Xiong Y; Zhao Y; Miao L; Lin CM; Huang L
J Control Release; 2016 Dec; 244(Pt A):63-73. PubMed ID: 27840166
[TBL] [Abstract][Full Text] [Related]
27. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
28. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
29. Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages.
Xu Y; Xu Z; Li Q; Guo L; Wang Y; Zhou J; Wang G; Liu Y
J Immunol Res; 2019; 2019():7478538. PubMed ID: 31781681
[TBL] [Abstract][Full Text] [Related]
30. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
31. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
32. Uncoupling protein 2 downregulation by hypoxia through repression of peroxisome proliferator-activated receptor γ promotes chemoresistance of non-small cell lung cancer.
Wang M; Li G; Yang Z; Wang L; Zhang L; Wang T; Zhang Y; Zhang S; Han Y; Jia L
Oncotarget; 2017 Jan; 8(5):8083-8094. PubMed ID: 28042952
[TBL] [Abstract][Full Text] [Related]
33. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
[TBL] [Abstract][Full Text] [Related]
34. Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway.
Liu Y; Hu F; Zhao L
J Nanosci Nanotechnol; 2021 Feb; 21(2):903-908. PubMed ID: 33183422
[TBL] [Abstract][Full Text] [Related]
35. IL-8 from CD248-expressing cancer-associated fibroblasts generates cisplatin resistance in non-small cell lung cancer.
Wu J; Zhang Q; Wu J; Yang Z; Liu X; Lou C; Wang X; Peng J; Zhang J; Shang Z; Xiao J; Wang N; Zhang R; Zhou J; Wang Y; Hu Z; Zhang R; Zhang J; Zeng Z
J Cell Mol Med; 2024 Feb; 28(4):e18185. PubMed ID: 38396325
[TBL] [Abstract][Full Text] [Related]
36. Endoplasmic Reticulum Stress Promotes Autophagy and Apoptosis and Reduces Chemotherapy Resistance in Mutant p53 Lung Cancer Cells.
Gan PP; Zhou YY; Zhong MZ; Peng Y; Li L; Li JH
Cell Physiol Biochem; 2017; 44(1):133-151. PubMed ID: 29130967
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
39. CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging.
Zhang T; Zhang P; Li HX
Int J Nanomedicine; 2021; 16():561-577. PubMed ID: 33542625
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
